Literature DB >> 20409220

Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.

Yasutomo Suzuki1, Yukihiro Kondo, Shuntaro Hara, Ryouji Kimata, Taiji Nishimura.   

Abstract

OBJECTIVES: To investigate the androgen response of hormone-dependent prostate cancer cells under hypoxia and to examine the effect of geldanamycin (GA), a heat shock protein 90 (Hsp90)-specific inhibitor, on the androgen response.
METHODS: LNCaP cells were cultured with or without GA under normoxic or hypoxic conditions. Cell viability was examined in response to dihydrotestosterone (DHT). Luciferase reporter gene assay was used to measure androgen response element (ARE)- and hypoxia response element (HRE)-mediated transcriptional activities. Western blot was used to analyze the protein levels of androgen receptor (AR), hypoxia-inducible factor-1alpha (HIF-1alpha) and Hsp90.
RESULTS: The DHT-dependent growth and ARE-mediated transcriptional activities of LNCaP cells were depressed under hypoxic conditions. However, these effects were recovered after incubation with GA. In contrast, hypoxia-induced HRE-mediated transcriptional activity, which was dose-dependently increased by DHT, was suppressed by GA. The expression of AR, HIF-1alpha and Hsp90 proteins were decreased under hypoxic conditions by adding GA.
CONCLUSIONS: Geldanamycin increases the androgen response regardless of AR protein in hormone-dependent prostate cancer cells under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409220     DOI: 10.1111/j.1442-2042.2010.02450.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

1.  Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.

Authors:  Giovanna Danza; Claudia Di Serio; Fabiana Rosati; Giuseppe Lonetto; Niccolò Sturli; Doreen Kacer; Antonio Pennella; Giuseppina Ventimiglia; Riccardo Barucci; Annamaria Piscazzi; Igor Prudovsky; Matteo Landriscina; Niccolò Marchionni; Francesca Tarantini
Journal:  Mol Cancer Res       Date:  2011-12-15       Impact factor: 5.852

2.  HEXIM1 controls P-TEFb processing and regulates drug sensitivity in triple-negative breast cancer.

Authors:  Hengyi Shao; Qingwei Zhu; Huasong Lu; Amanda Chang; Carol Gao; Qiang Zhou; Kunxin Luo
Journal:  Mol Biol Cell       Date:  2020-06-10       Impact factor: 4.138

3.  Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.

Authors:  Takeo Nomura; Mutsushi Yamasaki; Kenichi Hirai; Toru Inoue; Ryuta Sato; Keiko Matsuura; Masatsugu Moriyama; Fuminori Sato; Hiromitsu Mimata
Journal:  Mol Cancer       Date:  2013-04-08       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.